Iliac vein stents generally last well beyond five years for most patients. Five-year data from clinical studies show cumulative patency rates (meaning the stent remains open and functional) around 88% without any additional procedures. When re-interventions to maintain flow are included, that number climbs to roughly 99%. The biggest variable is why the stent was placed in the first place: stents placed for non-thrombotic compression hold up significantly better than those placed after a blood clot.
What the Long-Term Numbers Look Like
Stent “patency” is the key measure of longevity. It simply means the stent is open and blood is flowing through it. There are three ways doctors track this, and each tells a slightly different story about how long your stent will work.
Primary patency, the strictest measure, asks whether the stent stayed open on its own with no additional procedures. In a study following patients for five years, primary patency was 88.2%. Assisted-primary patency, which counts stents that stayed open with a minor tune-up procedure before they fully blocked, was 92.5%. Secondary patency, which includes stents that were reopened after a full blockage, reached 98.9%. In practical terms, this means that even in the small number of cases where a stent does close off, doctors can almost always restore flow.
Most stent failures happen in the first year. After that initial period, the risk of losing patency drops considerably. This early vulnerability is often tied to patients stopping their blood-thinning medication too soon or not taking it consistently.
Compression Stents vs. Post-Clot Stents
The reason you needed a stent has a major impact on how long it lasts. Patients fall into two broad categories: those with non-thrombotic iliac vein lesions (NIVL), where the vein is compressed by a nearby artery but no clot formed, and those with post-thrombotic syndrome (PTS), where a previous deep vein thrombosis damaged the vein wall.
The difference in outcomes is striking. In a large multicenter study, primary patency for NIVL patients was 99.3%, compared to 68.6% for PTS patients. Patients who had an acute clot that was recently treated fell in between at 83.6%. The scarring and inflammation left behind by a blood clot makes the vein lining rougher and more prone to re-narrowing, which explains the gap. If your stent was placed for May-Thurner syndrome or another compression issue without a history of clotting, you can expect especially durable results.
What Causes a Stent to Fail
Two factors stand out as the strongest predictors of stent re-occlusion. The first is chronic post-thrombotic damage in the vein. Patients with old, scarred veins had roughly seven times the risk of stent blockage compared to those without prior clot damage. The second is stent placement that extends below the junction where the iliac vein meets the large vein returning blood to the heart. Stents positioned lower carried about five and a half times the risk of closing off, likely because of increased turbulence and mechanical stress in that segment.
How long symptoms were present before stenting also mattered. Patients who waited longer before getting treated had significantly worse outcomes in initial analyses, suggesting that earlier intervention tends to produce more durable results. Interestingly, factors you might expect to matter, like BMI, smoking status, or inherited clotting disorders, did not reach statistical significance for predicting stent failure in the studies examined.
Incomplete clot removal before stent placement also increased the risk. When the clot-dissolving procedure only partially cleared the vein, the remaining debris created a surface where new clots could form around the stent.
Modern Stent Design
Early iliac vein stents were borrowed from arterial procedures and weren’t built for the unique demands of veins, which are thinner-walled and subject to external compression. Newer stents designed specifically for veins use a nickel-titanium alloy (nitinol) and are engineered with greater outward pushing force to resist the compression that caused the problem in the first place.
Despite the engineering improvements, head-to-head comparisons show that outcomes are similar between dedicated venous stents and older composite stent configurations. At 18 months, primary patency was 81% for the dedicated venous stent and 87% for the older approach, with no statistically significant difference. Both types achieved near-perfect secondary patency at 97% to 100%. The takeaway is that technique and patient selection matter at least as much as which specific stent is used.
Blood Thinners After Stenting
Staying on your prescribed blood-thinning medication is one of the most important things you can do to protect your stent. Expert consensus recommends at least 6 months of anticoagulation after stenting for an acute clot, and at least 12 months for post-thrombotic syndrome. In the first month after the procedure, more intensive blood-thinning regimens are typically used.
Given that most stent failures cluster in the first year and are linked to inadequate anticoagulation, completing your full course of medication is directly tied to long-term stent survival. Stopping early, even if you feel fine, is one of the most common and preventable causes of stent blockage.
Follow-Up and Monitoring
After stent placement, you’ll typically have an ultrasound at your first postoperative visit, then at periodic intervals. The median number of follow-up visits in large studies is about two, spread over roughly 20 months. These visits use duplex ultrasound to check blood flow through the stent and look for early signs of narrowing before a full blockage develops.
For patients whose stents were placed for vein compression alone, extended long-term surveillance may not be necessary once the stent is confirmed open and symptoms have resolved. Patients who had stents placed after a blood clot are a different story. Their stents continued to show failures beyond the six-month mark, so ongoing monitoring over a longer period provides a meaningful safety net. Catching a narrowing stent early allows for a minor procedure to restore flow before a complete blockage occurs, which is why the secondary patency numbers are so much higher than primary patency.